NCT05276323

Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children Study

Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children: an Open-label Randomized Pilot Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Soroka University Medical Center · Academic / Other
• Sex: All
• Age: 2 Years – 18 Years
• Healthy volunteers: Accepted

Summary

A randomized, open-label trial comparing Medihoney Derma Cream to Hydrocortisone 1% cream. Children between the ages of 2-18 years old diagnosed with mild to moderate atopic dermatitis with an IGA (Investigator Global Assessment) score of 2-3, and a BSA (Body Surface Area) score of 1%-10% were included.

Detailed description

A randomized trial comprising children aged 2-18 diagnosed with mild to moderate AD, with an IGA of 2-3 and BSA of 1%-10%, including 30 patients, 20 using Med-D-Cream and 10 as controls using Hydrocortisone 1% cream. Patients applied creams for 2 weeks and were then followed for two weeks to measure clinical responses and pruritus change.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Medihoney Derma Cream	applied topically, twice a day, on all affected areas in the body for two weeks.
DRUG	Hydrocortisone 1% cream	applied topically, twice a day, on all affected areas in the body for two weeks.

Timeline

• Start date: 2020-10-01
• Primary completion: 2021-02-28
• Completion: 2021-12-31
• First posted: 2022-03-11
• Last updated: 2022-03-11

Locations

1 site across 1 country: Israel